CytomX, Pfizer antibody drug deal is worth up to $635M

Pfizer and CytomX Therapeutics agreed to collaborate in the discovery and development of antibody-drug conjugates for cancer using the latter's Probody drug-development technology. The firms will conduct preclinical research, and Pfizer will get the rights to develop and market any chosen ADCs. The deal entitles CytomX to $25 million upfront and as much as $610 million in milestone fees plus sales royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · BioWorld (free content)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY